Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Partnershipocrelizumab biosimilarPositive

AI Analysis

Summary

Teva and Polpharma Biologics announced a global partnership for the development and commercialization of an ocrelizumab biosimilar. The deal expands both companies' biologic portfolios in the competitive biosimilar market.

Importance:6/10

Sentiment:

0.50

biosimilarpartnershipocrelizumabglobal_deal

Related Companies

$TEVA

Read the original article

Published by yahoo_finance on July 10, 2026 10:31 AM

Read Original